Unexpected Exacerbation of Neuroinflammatory Response After a Combined Therapy in Old Parkinsonian Mice

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Parkinson's disease (PD) is age-related, yet studies often use young animals.
• Drug repositioning for neurodegenerative disorders is promising.
• Individual antioxidant (N-acetylcysteine, NAC) and anti-inflammatory (HA-1077) drugs show neuroprotection in PD models.

Purpose of the Study:

• To evaluate the neuroprotective effect of combining NAC and HA-1077 in aged Parkinsonian mice.
• To investigate potential synergistic or antagonistic effects of these drugs in an aging PD model.

Main Methods:

• Aged (20-month-old) C57BL/6 mice were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to model Parkinson's disease.
• Mice received combined treatment of NAC and HA-1077.
• Neuroprotection was assessed by measuring dopaminergic neuronal death and glial activation (microglia and astrocytes) in the Substantia Nigra pars compacta (SNpc) and striatum.
• Astroglial response was further analyzed using co-immunostaining for GFAP, S100b, and p-JNK.

Main Results:

• Combined NAC+HA-1077 treatment significantly increased dopaminergic neuronal death in aged Parkinsonian mice.
• This combination also led to increased microglial and astroglial activation in the SNpc and striatum.
• Astroglial response, indicated by GFAP, S100b, and p-JNK, was notably exacerbated in the combined treatment group.
• Unexpected toxic effects were observed, contrasting with individual drug neuroprotective properties.

Conclusions:

• The combination of NAC and HA-1077 demonstrated unexpected toxicity in aged Parkinsonian mice.
• Elderly Parkinson's patients may experience exacerbated neurodegeneration from combined drug therapies, even those used for other age-related conditions.
• Careful consideration of drug interactions is crucial when designing therapeutic strategies for aging populations with neurodegenerative diseases.